Oncopeptides AB (publ) (LON:0RN4)
London
· Delayed Price · Currency is GBP · Price in SEK 1.916
-0.024 (-1.24%)
At close: Apr 24, 2025
Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of GBP 33.91 million. The enterprise value is 29.52 million.
| Market Cap | 33.91M |
| Enterprise Value | 29.52M |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +84.13% |
| Shares Change (QoQ) | +2.99% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 183.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.84 |
| PB Ratio | 8.65 |
| P/TBV Ratio | 8.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.44 |
| EV / Sales | 12.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 2.25.
| Current Ratio | 4.23 |
| Quick Ratio | 4.14 |
| Debt / Equity | 2.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -398.17 |
Financial Efficiency
Return on equity (ROE) is -512.51% and return on invested capital (ROIC) is -102.84%.
| Return on Equity (ROE) | -512.51% |
| Return on Assets (ROA) | -73.43% |
| Return on Invested Capital (ROIC) | -102.84% |
| Return on Capital Employed (ROCE) | -147.01% |
| Revenue Per Employee | 28,552 |
| Profits Per Employee | -256,764 |
| Employee Count | 80 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -40.50% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 62.25 |
| Average Volume (20 Days) | 2,714 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of GBP 2.28 million and -20.54 million in losses. Loss per share was -0.12.
| Revenue | 2.28M |
| Gross Profit | 2.09M |
| Operating Income | -20.46M |
| Pretax Income | -20.51M |
| Net Income | -20.54M |
| EBITDA | -20.29M |
| EBIT | -20.46M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 12.89 million in cash and 8.80 million in debt, giving a net cash position of 4.09 million.
| Cash & Cash Equivalents | 12.89M |
| Total Debt | 8.80M |
| Net Cash | 4.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.92M |
| Book Value Per Share | 0.02 |
| Working Capital | 11.96M |
Cash Flow
| Operating Cash Flow | -18.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 91.59% |
| Operating Margin | -895.78% |
| Pretax Margin | -898.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -84.13% |
| Shareholder Yield | -84.13% |
| Earnings Yield | -60.58% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |